» Articles » PMID: 36403423

Retrospective Immunogenicity Analysis of Seasonal Flu H3N2 Vaccines Recommended in the Past Ten Years Using Immunized Animal Sera

Overview
Journal EBioMedicine
Date 2022 Nov 20
PMID 36403423
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Influenza A (H3N2) virus (A/H3N2) has complex antigenic evolution, resulting in frequent vaccine strain updates. We aimed to evaluate the protective effect of the vaccine strains on the circulating strains from past ten years and provide a basis for finding a broader and more efficient A/H3N2 vaccine strain.

Methods: Eighty-four representative circulating A/H3N2 strains were selected from 65,791 deposited sequences in 2011-2020 and pseudotyped viruses were constructed with the VSV vector. We immunized guinea pigs with DNA vaccine containing the A/H3N2 components of the vaccine strains from 2011 to 2021 and tested neutralizing antibody against the pseudotyped viruses. We used a hierarchical clustering method to classify the eighty-four representative strains into different antigenic clusters. We also immunized animals with monovalent vaccine stock of the vaccine strains for the 2020-2021 and 2021-2022 seasons and tested neutralizing antibody against the pseudotyped viruses.

Findings: The vaccine strains PE/09, VI/11 and TE/12 induced higher levels of neutralizing antibody against representative strains circulating in recommended year and the year immediately prior whereas vaccine strains HK/14, HK/19 and CA/20 induced poor neutralization against all representative strains. The representative strains were divided into five antigenic clusters (AgV), which were not identical to gene clades. The AgV5 strains were most difficult to be protected among the five clusters. Compared with single-dose immunization, three doses of monovalent vaccine stock (HK/19 or CA/20) could induce stronger and broader neutralizing antibodies against strains in each of the antigenic clusters.

Interpretation: The protective effect of vaccine strains indicated that the accurate selection of A/H3N2 vaccine strains must remain a top priority. By increasing the frequency of immunization, stronger and broader neutralizing antibodies against strains in all antigenic clusters were induced, which provides direction for a new immunization strategy.

Funding: This work was supported by a grant from National Key R&D Program of China (No. 2021YFC2301700).

Citing Articles

A single mutation at position 214 of influenza B hemagglutinin enhances cross-neutralization.

Cheng Z, Sun Y, Shen Y, Wu X, Pan L, Wu H Emerg Microbes Infect. 2025; 14(1):2467770.

PMID: 39960410 PMC: 11849025. DOI: 10.1080/22221751.2025.2467770.


Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains.

Huang X, Cheng Z, Lv Y, Li W, Liu X, Huang W Hum Vaccin Immunother. 2024; 20(1):2380111.

PMID: 39205645 PMC: 11364067. DOI: 10.1080/21645515.2024.2380111.


The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research.

Zhang X, Zhou Z Vaccines (Basel). 2023; 11(7).

PMID: 37514959 PMC: 10384589. DOI: 10.3390/vaccines11071143.